|
Synonyms: AK-112 | AK112 | SMT-112 | SMT112
Compound class:
Antibody
Comment: Ivonescimab (AK112/SMT112) is a first-in-class anti-programmed death-1 (PD-1)/VEGF-A bispecific monoclonal antibody. It is designed to simultaneously block both PD-1 and VEGF-mediated immunosuppression in the tumour microenvironment (TME) and inhibit the pro-angiogenic action of VEGF. Interaction of ivonescimab with VEGF-A increases the antibody's avidity for PD-1 and enhances the inhibitory effect on PD-1/PD-L1 signalling [4].
|
| Immunopharmacology Comments |
| Ivonescimab is designed to block the immunosuppressive effects of both PD-1 and VEGF in the TME. |
